AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results
Growth Buoyant Despite Vaccine Complications
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.
You may also be interested in...
An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.
Lilly’s second-quarter earnings announcement relegated its core business in favor of its experimental Alzheimer’s disease drug. This diverted attention away from competitive reimbursement challenges that may be affecting its insulin business.
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.